Precision medicine in neurodegeneration: the IHI-PROMINENT project

Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in elderly. In Europe, over 14 million people currently living with dementia, at a cost 400 billion EUR annually. Recent advances diagnostics approval for new pharmaceutical treatments Alzheimer’s disease (AD), common etiology heralds beginning precision medicine this field. However, their implementation will challenge an already over-burdened healthcare systems. There is need innovative digital solutions that can drive related clinical pathways optimize personalize care delivery. Public-private partnerships ideal vehicles tackle these challenges. Here we describe Innovative Health Initiative (IHI) public-private partnership project PROMINENT has been initiated by connecting leading dementia researchers, medical professionals, patients partners latest health technologies using based platform. The builds upon knowledge implemented tools from several collaborative initiatives address models early detection, diagnosis, monitoring AD other neurodegenerative disorders. aims provide support improvement efforts each aspect pathway including prognosis, treatment, data collection real world evidence effectiveness studies. Ultimately expected lead cost-effective improved outcomes.